Inflammatory bowel disease and hepatitis B and C in Western Balkans: A referral centre study and review of the literature

Journal of Crohn's and Colitis

Volumn 4, Issue 4, 2010, Pages 450-465

  Katsanos, Konstantinos H ^a   Tsianos, Vasileios E ^a   Zois, Christos D ^a   Zioga, Heleni ^a   Vagias, Ioannis ^a   Zervou, Eleftheria ^b   Christodoulou, Dimitrios K ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Crohn's disease; Hepatitis B; Hepatitis C; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA1 INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; RIBAVIRIN; TENOFOVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOID; CAUSE OF DEATH; COHORT ANALYSIS; CROHN DISEASE; DISEASE EXACERBATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; GREECE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GREECE; HEPATITIS B; HEPATITIS C; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREVALENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77957325399     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.03.001     Document Type: Article

References (70)

1. Villa F., Rumi M.G., Signorelli C., Saibeni S., Del Ninno E., Ferrero Bogetto S., et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol 2005, 17(11):1243-1245.
2. Scherzer T.M., Staufer K., Novacek G., Steindl-Munda P., Schumacher S., Hofer H., et al. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment Pharmacol Ther 2008, 28:742-748.
3. Esteve M., Saro C., González-Huix F., Suarez F., Forné M., Viver J.M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
4. Biancone L., Pavia M., Del Vecchio Blanco G., D'Incà R., Castiglione F., De Nigris F., et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001, 7:287-294. Italian Group for the Study of the Colon and Rectum (GISC).
5. Bargiggia S., Thorburn D., Anderloni A., Ardizzone S., Giorgi A., Bianchi Porro G., et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005, 22:209-215.
6. Longo F., Hebuterne X., Tran A., Staccini P., Hastier P., Schneider S., et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol 2000, 24:77-81.
7. Tolentino Y.F., Fogaca H.S., Zaltman C., Ximenes L.L., Coelho H.S. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital. World J Gastroenterol 2008, 14:3201-3206.
8. Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, et al. GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57-63. Erratum in: Am J Gastroenterol 2009;104:801.
9. Chevaux J.B., Nani A., Oussalah A., Venard V., Bensenane M., Belle A., et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010, 16:916-924.
10. Broomé U., Glaumann H., Hellers G., Nilsson B., Sörstad J., Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994, 35:84-89.
11. Goritsas C., Papadopoulos N., Trigidou R., Tzathas H. Primary sclerosing cholangitis lesions in a patient with Crohn's disease and HCV infection. J Gastrointestin Liver Dis 2007, 16:222-223.
12. Wörns M.A., Lohse A.W., Neurath M.F., Croxford A., Otto G., Kreft A., et al. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Am J Gastroenterol 2006, 101:1931-1937.
13. Horn T.L., Reynolds J., de Villiers W., Peña L.R. Hepatitis C virus and inflammatory bowel disease. Dig Dis Sci 2009, 54:1171-1177.
14. De Diego Lorenzo A., Kashoob M., Romero M., Parera A., Durán F., Piqueras B., et al. Treatment with recombinant interferon alfa-2b of a patient with chronic hepatitis C and concomitant ulcerative colitis. Rev Esp Enferm Dig 1997, 89:399-401.
15. Cottone M., Magliocco A., Trallori G., Brignola C., Vandelli C., Ardizzone S., et al. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol 1995, 27:3-4.
16. Tilg H., Vogelsang H., Ludwiczek O., Lochs H., Kaser A., Colombel J.F., et al. A randomised placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728-1733.
17. Holtmann M.H., Galle P.R., Neurath M.F. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003, 98:504-505.
18. Esteve M., Loras C., González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007, 13:1450-1451.
19. Katsanos K.H., Christodoulou D.K., Zervou E., Babameto A., Kraja B., Hyphantis H., et al. Hepatitis B remains a major health priority in Western Balkans: results of a 4-year prospective Greek-Albanian collaborative study. Eur J Int Med 2009, 20:698-702.
20. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009, 29:1-8.
21. Ojiro K., Naganuma M., Ebinuma H., Kunimoto H., Tada S., Ogata H., et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008, 43:397-401.
22. Colbert C., Chavarria A., Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007, 13:1453-1454.
23. Madonia S., Orlando A., Scimeca D., Olivo M., Rossi F., Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007, 13:508-509.
24. Millonig G., Kern M., Ludwiczek O., Nachbaur K., Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 2006, 12(6):974-976.
25. Ueno Y., Tanaka S., Shimamoto M., Miyanaka Y., Hiyama T., Ito M., et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005, 50:163-166.
26. Wendling D., Auge B., Bettinger D., Lohse A., Le Huede G., Bresson-Hadni S., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005, 64:788-789.
27. Sikorska-Wiśniewska G., Liberek A., Bako W., Góra-Gebka M. Therapeutic difficulties in a patient with ulcerative colitis and concomitant HBV and HCV infection. Med Wieku Rozwoj 2004, 8(2 Pt 2):377-382.
28. Oniankitan O., Duvoux C., Challine D., Mallat A., Chevalier X., Pawlotsky J., et al. Infliximab therapy for rheumatic disease in patients with chronic hepatitis B or C. J Rheumatol 2004, 31:107-109.
29. del Valle García-Sánchez M., Gómez-Camacho F., Poyato-González A., Iglesias-Flores E.M., de Dios-Vega J.F., Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004, 10:701-702.
30. Papadakis K.A., Matuk R., Abreu M.T., Vasiliauskas E.A., Fleshner P.R., Lechago J., et al. Crohn's ileitis after liver transplantation from a living-related donor with Crohn's disease. Gut 2004, 53:1389-1390.
31. Ostuni P., Botsios C., Punzi L., Sfriso P., Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003, 62:686-687.
32. Michel M., Duvoux C., Hezode C., Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult Still's disease. J Rheumatol 2003, 30:1624-1625.
33. Kanazawa N., Izumi N., Kawamura S., Tsuchiya K., Hamano K., Itakura J., et al. Ulcerative colitis developed after acute exacerbation of chronic hepatitis B. Nippon Naika Gakkai Zasshi 2002, 91:2192-2195.
34. Ramji A., Owen D.A., Erb S.R., Scudamore C.H., Yoshida E.M. Post-liver transplant Crohn's disease:graft tolerance but not self-tolerance?. Dig Dic Sci 2002, 47:522-527.
35. Biancone L., Del Vecchio Blanco G., Pallone F., Castiglione F., Bresci G., Sturniolo G. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002, 122:593-594. Italian Group for the Study of the Colon and Rectum.
36. Legaz Huidobro M.L., Artaza Varasa T., Alcántara Torres M., Sánchez Ruano J.J., López Carriches I., Martínez Potenciano J.L. Recombinant alfa-2 interferon treatment of a patient with chronic hepatitis B and ulcerative colitis. Gastroenterol Hepatol 1996, 19:55-57.
37. Yasumori K., Aramaki T., Mizuta Y., Nomoto T., Mukai N., Tanaka Y. Exacerbation of ulcerative colitis and chronic hepatitis by the treatment with interferon for chronic hepatitis B. Nippon Shokakibyo Gakkai Zasshi 1995, 92:1066-1070.
38. Suzuki H., Sata M., Yano Y., Hidaka R., Sasaki E., Abe H., et al. A case of chronic hepatitis type B with Crohn's disease. Nippon Shokakibyo Gakkai Zasshi 1986, 83:1387-1391.
39. Miike T., Tahara Y., Yamaguchi Y., Harada T., Abe H., Kusumoto K., et al. A case study: interferon-beta-induced remission of ulcerative colitis in a patient with type C chronic hepatitis. Nippon Shokakibyo Gakkai Zasshi 2008, 105:1362-1366.
40. Abdelmalek M.F., Liu C., Valentine J.F. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol 2007, 102:1333-1334.
41. Tursi A. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C. Inflamm Bowel Dis 2007, 13:1189-1190.
42. Watanabe T., Inoue M., Harada K., Homma N., Uchida M., Ogata N., et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut 2006, 55:1682-1683.
43. Bongiovanni M., Ranieri R., Ferrero S., Casanova F., Monforte A. Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin. AIDS 2006, 20:1989-1990.
44. Salcedo-Mora X., Maté J., Medina J., Nam Cha S.J., Gisbert J.P., Moreno-Otero R. Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion 2006, 73:210-214.
45. Sprenger R., Sagmeister M., Offner F. Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut 2005, 54:438-439.
46. Alderson J.W., Van Dinter T.G., Opatowsky M.J., Burton E.C. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. Med Gen Med 2005, 7:7.
47. Nagai H., Matsumaru K., Shiozawa K., Momiyama K., Wakui N., Shinohara M., et al. Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation. J Gastroenterol 2005, 40:848-853.
48. Sawada K., Ohnishi K., Kusaka T., Matoba Y., Fukunaga K. Dramatic response to granulocytapheresis in a Crohn's disease case complicated by hepatitis C virus. Dig Dis Sci 2005, 50:1533-1534.
49. Khalil A., Lucidarme D., Desurmont P., Hamdan-Khalil R., Filoche B. Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C. Gastroenterol Clin Biol 2005, 29:193-196.
50. Peterson J.R., Hsu F.C., Simkin P.A., Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003, 62:1078-1082.
51. Sawada K., Ohnishi K., Fukunaga K., Shimoyama T. A new treatment for HCV-ulcerative colitis comorbidity intolerant to INF-alpha. Am J Gastroenterol 2003, 98:228-229.
52. Awakawa T., Hirohashi S., Hasegawa K., Tsukuda H., Ibayashi Y., Hirane T., et al. A case of acute phase ulcerative colitis like colitis developed by the interferon-beta therapy for chronic hepatitis C. Nippon Shokakibyo Gakkai Zasshi 2003, 100:680-684.
53. Niki T., Nishida K., Honsako Y., Matsumura Y., Ueno H., Fujimi T., et al. A case of ulcerative colitis along with characteristic features on computed tomography (CT), developed by the treatment with interferon for chronic hepatitis C. Nippon Shokakibyo Gakkai Zasshi 2001, 98:399-404.
54. Campbell S., Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001, 13:191-192.
55. Mavrogiannis C., Papanikolaou I.S., Elefsiniotis I.S., Psilopoulos D.I., Karameris A., Karvountzis G. Ulcerative colitis associated with interferon treatment for chronic hepatitis C. J Hepatol 2001, 34:964-965.
56. Usami T., Kurita Y., Nagae H., Ushiyama T., Suzuki K., Fujita K. Interferon induced ulcerative colitis-like acute colitis. Rinshohinyokika 1999, 53:54-57.
57. Yamamoto Y., Sakatani N., Yano S., Kou K., Ochi S., Yoshida Y., et al. Interferon induced IBD-like acute colitis-two cases of patients with chronic active hepatitis. Nippon Shokakibyo Gakkai Zasshi 1995, 92:1293-1296.
58. Mitoro A., Yoshikawa M., Yamamoto K., Mimura M., Yoshikawa Y., Shiroi A., et al. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med 1993, 32:327-331.
59. Honda K., Tsuruya T., Ito T., Ohsawa Y. A case of incidence of ulcerative colitis during the therapy of interferon for hepatitis C. Nippon Shokakibyo Gakkai Zasshi 1993, 90:1085.
60. Gasché C., Reinisch W., Vogelsang H., Pötzi R., Markis E., Micksche M., et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995, 40:800-804.
61. Sumer N., Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995, 7:597-602.
62. Madsen S.M., Schlichting P., Davidsen B., Nielsen O.H., Federspiel B., Riis P., et al. An open-labeled randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left sided ulcerative colitis. Am J Gastroenterol 2001, 96:1807-1815.
63. Perrillo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009-1022.
64. Eckhardt R., Kloos P., Dierich M.P., Meyer zum Büschenfelde K.H. K-lymphocytes (killer-cells) in Crohn's disease and acute virus B-hepatitis. Gut 1977, 18:1010-1016.
65. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 2009, 58:501-508.
66. Tsianos E.V., Katsanos K. Do we really understand what the immunological disturbances in inflammatory bowel disease mean?. World J Gastroenterol 2009, 15:521-525.
67. Nathan D.M., Angus P.W., Gibson P.R. Hepatitis B and C virus infections and anti-tumro necrosis factor-a therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006, 21:1366-1371.
68. Shibolet O., Ilan Y., Gillis S., Hubert A., Shouval D., Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002, 15(100):391-396.
69. Canbay A., Bechmann L.P., Best J., Jochum C., Treichel U., Gerken G. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z Gastroenterol 2006, 44:245-248.
70. Vantrappen G., Coremans G., Janssens J., Rutgeerts P. Does intercurrent hepatitis have a beneficial effect on the course of Crohn's disease?. Gastroenterology 1983, 84:843-845.